The study showed that RA patients who achieved an early response at 6 months were found to have significantly higher IgM rheumatoid factor titers at baseline compared to non-responders (mean 169.95 ± 176.19 mg/l, P <0.01). The gene discussed is CD40LG; the disease is rheumatoid arthritis.